Clinical Trial: Evaluation of Crisaborole 2% Versus Tacrolimus 0.1% Each Combined With Excimer Light in the Treatment of Stable Non-segmental Facial Vitiligo: a Prospective Randomized Controlled Study.

U.S., Oct. 30 -- ClinicalTrials.gov registry received information related to the study (NCT07904910) titled 'Evaluation of Crisaborole 2% Versus Tacrolimus 0.1% Each Combined With Excimer Light in the Treatment of Stable Non-segmental Facial Vitiligo: a Prospective Randomized Controlled Study.' on Oct. 23.

Brief Summary: The goal of this clinical trial is to learn if topical application of crisaborole 2% ointment can treat stable patches of facial vitiligo in pediatrics and adult patients of both genders. It will also learn about the safety of crisaborole 2% ointment.

The main questions it aims to answer is:

* Does crisaborole 2% ointment work effectively in stable localized facial vitiligo in pediatrics and adults?

* is crisaborole 2% ...